All In Biotech

Drug Trial Radar · NCT04219826

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Jan 10, 2020

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Lead sponsor
CytokineticsIndustry
Sponsor type
Industry
First posted
Jan 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

  • CK-3773274 (5 - 15 mg)Drug

    CK-3773274 tablets administered orally once daily

  • CK-3773274 (10 - 30 mg)Drug

    CK-3773274 tablets administered orally once daily

  • Placebo for CK-3773274Drug

    Placebo administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: 14 weeks
  2. Incidence of Left Ventricular Ejection Fraction (LVEF) < 50%Time frame: 14 weeks
  3. Incidence of Serious Adverse Events (SAEs)Time frame: 14 weeks

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Cedar-Sinai Medical Center

    Los Angeles, California

  • UCSF Medical Center

    San Francisco, California

  • Northwestern University

    Evanston, Illinois

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Michigan Medicine - University of Michigan

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • New York University Langone Health Medical Center

    New York, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Duke Cardiology at Southpoint

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)

    Philadelphia, Pennsylvania

  • UMPC Heart and Vascular Institute

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Intermountain Medical Center

    Murray, Utah

  • University of Virginia Health System

    Charlottesville, Virginia

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Erasmus University Medical Center (Erasmus MC)

    Rotterdam, Netherlands

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, Spain

  • Hospital Universitario Puerta de Hierro de Majadahonda

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.